We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

150 hedge funds and large institutions have $1.73B invested in Ventyx Biosciences in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 30

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

4.44% more ownership

Funds ownership: 85.47%89.91% (+4.4%)

3% more funds holding

Funds holding: 146150 (+4)

4% more capital invested

Capital invested by funds: $1.67B → $1.73B (+$59.7M)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

77% less call options, than puts

Call options by funds: $7.2M | Put options by funds: $31.6M

Holders
150
Holders Change
+4
Holders Change %
+2.74%
% of All Funds
2.36%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
29
Increased
70
Reduced
30
Closed
25
Calls
$7.2M
Puts
$31.6M
Net Calls
-$24.4M
Net Calls Change
-$30.2M
Name Holding Trade Value Shares
Change
Change in
Stake
NC
126
NinePointTwo Capital
California
$253K +$267K +7,741 New
EWM
127
Evercore Wealth Management
New York
$235K +$247K +7,170 New
ECM
128
ExodusPoint Capital Management
New York
$229K -$6.17M -179,055 -96%
MC
129
Moors & Cabot
Massachusetts
$216K
Handelsbanken Fonder
130
Handelsbanken Fonder
Sweden
$210K +$221K +6,400 New
AB
131
Amalgamated Bank
New York
$204K +$92.8K +2,692 +76%
US Bancorp
132
US Bancorp
Minnesota
$201K -$26.7K -775 -11%
Zurich Cantonal Bank
133
Zurich Cantonal Bank
Switzerland
$189K +$110K +3,184 +123%
CSS
134
Cubist Systematic Strategies
Connecticut
$137K +$144K +4,179 New
AIP
135
Ameritas Investment Partners
Nebraska
$127K +$64.5K +1,870 +94%
VEA
136
Virtus ETF Advisers
New York
$102K +$4.24K +123 +4%
MLICM
137
Metropolitan Life Insurance Company (MetLife)
New York
$84.4K +$42.8K +1,242 +93%
TWC
138
TD Waterhouse Canada
Ontario, Canada
$42.3K
CUAMC
139
China Universal Asset Management Company
China
$25.2K
Nisa Investment Advisors
140
Nisa Investment Advisors
Missouri
$23.6K +$24.2K +703 +3,906%
TRCT
141
Tower Research Capital (TRC)
New York
$22.1K +$7.89K +229 +52%
CG
142
Cutler Group
California
$22K +$24.1K +700 New
CA
143
Clearstead Advisors
Ohio
$16.4K +$17.2K +500 New
Allspring Global Investments
144
Allspring Global Investments
North Carolina
$15K +$15.7K +456 New
Osaic Holdings
145
Osaic Holdings
Arizona
$7.18K -$3.76K -109 -33%
Daiwa Securities Group
146
Daiwa Securities Group
Japan
$7K
QCG
147
Quadrant Capital Group
Ohio
$1.38K
Carson Wealth (CWM LLC)
148
Carson Wealth (CWM LLC)
Nebraska
$1K
Allianz Asset Management
149
Allianz Asset Management
Germany
$735 +$772K +22,400 New
RI
150
RTW Investments
New York
-$46.5M -1,388,881 Closed

VTYX Hedge Fund Activity: Q2 2023 in Review

150 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2023, worth a combined $1.73B — up 3.6% from $1.67B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new VTYX positions and 25 closed out — a net gain of 4 holders — while 70 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.6M. The largest seller was venBio Partners, cutting an estimated $64.6M.

  • 150 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2023, up from 146 in Q1 2023.
  • Funds reported $1.73B of Ventyx Biosciences stock for Q2 2023, up 3.6% quarter-over-quarter.
  • 29 funds opened new Ventyx Biosciences positions in Q2 2023 and 25 closed out, a net change of +4 holders.
  • The largest Ventyx Biosciences buyer in Q2 2023 was T. Rowe Price Associates, an estimated $43.6M added.
  • The largest Ventyx Biosciences seller in Q2 2023 was venBio Partners, an estimated $64.6M sold.

Based on aggregated 13F filings for Q2 2023.